TY - JOUR
T1 - Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma
AU - Okusaka, Takuji
AU - Okada, Shuichi
AU - Ishii, Hiroshi
AU - Ikeda, Masafumi
AU - Nakasuka, Hidekazu
AU - Nagahama, Hiroyasu
AU - Iwata, Ryoko
AU - Furukawa, Hiroyoshi
AU - Takayasu, Kenichi
AU - Nakanishi, Yukihiro
AU - Sakamoto, Michiie
AU - Hirohashi, Setsuo
AU - Yoshimori, Masayoshi
PY - 1998/7/1
Y1 - 1998/7/1
N2 - Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as @? 50% reduction and/or @? 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.
AB - Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as @? 50% reduction and/or @? 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.
KW - Hepatocellular carcinoma
KW - Transarterial chemotherapy
KW - Zinostatin stimalamer
UR - http://www.scopus.com/inward/record.url?scp=0031840933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031840933&partnerID=8YFLogxK
U2 - 10.1159/000011863
DO - 10.1159/000011863
M3 - Article
C2 - 9663415
AN - SCOPUS:0031840933
SN - 0030-2414
VL - 55
SP - 276
EP - 283
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 4
ER -
